| Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov., 2018 | 511* | 2018 |
| Complete surgical excision is essential for the management of patients with breast implant–associated anaplastic large-cell lymphoma MW Clemens, LJ Medeiros, CE Butler, KK Hunt, MA Fanale, S Horwitz, ... Journal of Clinical Oncology 34 (2), 160-168, 2016 | 496 | 2016 |
| Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy P Jayaprakash, M Ai, A Liu, P Budhani, T Bartkowiak, J Sheng, C Ager, ... The Journal of clinical investigation 128 (11), 5137-5149, 2018 | 340 | 2018 |
| The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia P Williams, S Basu, G Garcia‐Manero, CS Hourigan, KA Oetjen, ... Cancer 125 (9), 1470-1481, 2019 | 298 | 2019 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 288 | 2020 |
| Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ... Blood advances 4 (7), 1311-1320, 2020 | 153 | 2020 |
| Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia NJ Short, G Montalban-Bravo, H Hwang, J Ning, MJ Franquiz, ... Blood advances 4 (22), 5681-5689, 2020 | 146 | 2020 |
| Analyzing length-biased data with semiparametric transformation and accelerated failure time models Y Shen, J Ning, J Qin Journal of the American Statistical Association 104 (487), 1192-1202, 2009 | 137 | 2009 |
| Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes GN Tamamyan, HM Kantarjian, J Ning, P Jain, K Sasaki, KL McClain, ... Cancer 122 (18), 2857-2866, 2016 | 133 | 2016 |
| Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens A Maiti, CR Rausch, JE Cortes, N Pemmaraju, NG Daver, F Ravandi, ... Haematologica 106 (3), 894, 2020 | 130 | 2020 |
| Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery B Badgwell, J Stanley, GJ Chang, MHG Katz, HY Lin, J Ning, SV Klimberg, ... Journal of surgical oncology 108 (3), 182-186, 2013 | 130 | 2013 |
| Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis ESHB Kanwal F, Khaderi S, Singal AG, Marrero JA, Loo N, Asrani SK, Amos CI ... Hepatology, 2022 | 93* | 2022 |
| Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy HA Abbas, D Hao, K Tomczak, P Barrodia, JS Im, PK Reville, Z Alaniz, ... Nature communications 12 (1), 6071, 2021 | 93 | 2021 |
| Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment‐related mortality A Maiti, W Qiao, K Sasaki, F Ravandi, TM Kadia, EJ Jabbour, NG Daver, ... American journal of hematology 96 (3), 282-291, 2021 | 90 | 2021 |
| Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) N Daver, S Basu, G Garcia-Manero, JE Cortes, F Ravandi, EJ Jabbour, ... Blood 128 (22), 763, 2016 | 90 | 2016 |
| Next‐generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma MT Tetzlaff, RR Singh, EG Seviour, JL Curry, CW Hudgens, D Bell, ... The Journal of pathology 240 (1), 84-95, 2016 | 87 | 2016 |
| Maximum likelihood estimations and EM algorithms with length-biased data J Qin, J Ning, H Liu, Y Shen Journal of the American Statistical Association 106 (496), 1434-1449, 2011 | 80 | 2011 |
| Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients HS Sa, ML Rubin, S Xu, J Ning, M Tetzlaff, O Sagiv, TJ Kandl, B Esmaeli British Journal of Ophthalmology 103 (7), 980-984, 2019 | 79 | 2019 |
| Identification of Novel Autoantibodies Associated with Psoriatic Arthritis Yuan, Y., Qiu, J., Lin, Z.T., Li, W., Haley, C., Mui, U.N., Ning, J., Tyring ... Arthritis & Rheumatology., 2019 | 78 | 2019 |
| Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia A Maiti, CD DiNardo, SA Wang, J Jorgensen, TM Kadia, NG Daver, ... Blood advances 5 (7), 1876-1883, 2021 | 76 | 2021 |
